What Is Patadin DS Ophthalmic Solution Eye Drop 0.2% Indications and Uses?

Patadin DS eye drops is indicated for the treatment of signs and symptoms (itchy, watery, red and swollen eyes and/or eyelids) of allergic conjunctivitis including vernal keratoconjunctivitis, vernal keratitis, blepharitis, blepharoconjunctivitis and giant papillary conjunctivitis ... Read more Patadin DS eye drops is indicated for the treatment of signs and symptoms (itchy, watery, red and swollen eyes and/or eyelids) of allergic conjunctivitis including vernal keratoconjunctivitis, vernal keratitis, blepharitis, blepharoconjunctivitis and giant papillary conjunctivitis. Patadin DS Nasal Spray is indicated for the relief of the symptoms of seasonal allergic rhinitis in adults and children 6 years of age and older. Patadin DS tablet is indicated in the treatment of allergic rhinitis (swelling of the nasal membranes caused by an allergy to pollen and mold spores in the air) and allergic skin conditions. It helps to relieve allergy symptoms such as skin rashes, swelling, hives (itchy, painful eruptions that sting), itching, sneezing, runny or stuffy nose.

Pharmacology (Source, Chemical and Physical Composition) Of Patadin DS Ophthalmic Solution Eye Drop 0.2%

Olopatadine, an antihistamine, works by blocking the action of histamine in the body, which reduces allergy symptoms. Patadin DS Ophthalmic Solution Eye Drop 0.2% (Olopatadine Hydrochloride) treats sneezing, itching, runny nose, and other nasal symptoms of allergies. Mode of Action : Olopatadine is an anti-allergic molecule that works via several mechanisms. As a mast cell stabilizer, it stabilizes rodent basophils and human conjunctival mast cells and inhibits the immunologically-stimulated release of histamine. Olopatadine acts as an antagonist at the histamine H1 receptors with high selectivity, Upon binding, olopatadine blocks the H1 receptor signaling pathway, inhibiting the release of inflammatory mediators, such as tryptase, prostaglandin D2, TNF-alpha, as well as pro-inflammatory cytokines. Pharmacokinetics : Absorption: Olopatadine was absorbed with individual peak plasma concentrations observed between 30 minutes and 1 hour after twice daily intranasal administration of Olopatadine Nasal Spray. Distribution: The protein binding of olopatadine was moderate at approximately 55% in human serum, and independent of drug concentration over the range of 0.1 to 1000 ng/mL. Metabolism: Olopatadine is not extensively metabolized. Based on plasma metabolite profiles of olopatadine, at least six minor metabolites circulate in human plasma. Elimination: The plasma elimination half-life of olopatadine is 8 to 12 hours. Olopatadine is mainly eliminated through urinary excretion

Drug Interactions of Patadin DS Ophthalmic Solution Eye Drop 0.2%

Formal drug-drug interaction studies were not conducted for Patadin DS Nasal Spray. Drug interactions with inhibitors of liver enzymes are not anticipated because Patadin DS Ophthalmic Solution Eye Drop 0.2% (Olopatadine Hydrochloride) is eliminated predominantly by renal excretion. Drug interactions involving P450 inhibition and plasma protein binding are also not expected.

Side Effects of Patadin DS Ophthalmic Solution Eye Drop 0.2%

Rarely headaches have been reported. Other adverse effects: asthenia, blurred vision, burning or stinging, cold syndrome, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, nausea, pharyngitis, pruritus, rhinitis, sinusitis, and taste perversion.

Precautions And Warnings for Patadin DS Ophthalmic Solution Eye Drop 0.2%

Patients should be advised not to wear a contact lens if their eye is red. Patadin DS ophthalmic solution should not be used to treat contact lens related irritation. Benzalkonium Chloride, preservative of Patadin, may be absorbed by soft contact lenses. Patients who wear soft contact lenses and whose eyes are not red should be instructed to wait at least 10 minutes after instillation of Patadin eye drops before they insert their contact lenses. The treatment should be discontinued in the presence of an allergic reaction. Before initial use, Patadin DS Nasal Spray by releasing 5 sprays or until a fine mist appears. When Patadin DS Nasal Spray has not been used for more than 7 days, re-prime by releasing 2 sprays. Avoid spraying Patadin DS Nasal Spray into the eyes. Patients should be informed to avoid spraying Patadin DS Nasal Spray in their eyes. Olonex Tablet should be used as prescribed by your doctor. Take it at the same time every day to maintain a constant level of this medicine in your body. Avoid taking more than the recommended dose. Do not stop taking this medicine without consulting your doctor, as your symptoms may reoccur.

Use During Pregnancy and Lactation

Patadin DS Ophthalmic Solution Eye Drop 0.2% (Olopatadine Hydrochloride) was found not to be teratogenic in rats and rabbits. There are, however, no adequate and well controlled studies in pregnant women. This drug should be used in pregnant women only if the potential benefit justifies the potential risk to the fetus. It is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities in the human breast milk. Nevertheless, caution should be exercised when Olopatadine is administered to a nursing mother.

Therapeutic Class

Ophthalmic Non-Steroid drugs

Storage Conditions of It

Store at room temperature and protect from light. It is desirable that the contents should not be used more than one month after first opening of the bottle. Pack Image: Patadin DS 0.2% Eye Drop Thanks for using MedEx! How would you rate your experience so far?